Enhancing prediction of thrombosis associated with breast cancer using prechemotherapy hematologic and coagulation characteristics.

IF 1.2 4区医学 Q4 HEMATOLOGY

Blood Coagulation & Fibrinolysis Pub Date : 2025-05-06 DOI:10.1097/MBC.0000000000001367

Regan Bucciol, Hannah Parente, Yousra Tera, E Claire Bunker, Aditi Kini, Brooke E Wilson, Mihaela Mates, Maha Othman

{"title":"Enhancing prediction of thrombosis associated with breast cancer using prechemotherapy hematologic and coagulation characteristics.","authors":"Regan Bucciol, Hannah Parente, Yousra Tera, E Claire Bunker, Aditi Kini, Brooke E Wilson, Mihaela Mates, Maha Othman","doi":"10.1097/MBC.0000000000001367","DOIUrl":null,"url":null,"abstract":"Introduction: The applicability of venous thromboembolism (VTE) risk assessment models (RAMs), to breast cancer (BC) populations remains unclear. We aimed to compare the efficacy of current RAMs and examine the potential of additional hematologic parameters and thromboelastography (TEG); a point of care test, in improving VTE prediction in breast cancer (BC) patients.Methods: In this pilot study, female BC patients were recruited before chemotherapy and followed for 6-12 months for VTE. VTE risk was assessed using Khorana score, Vienna CATS, PROTECHT, COMPASS-CAT, New Vienna CATSCORE, MDACC CAT, and hypercoagulability status. TEG and hematologic parameters were analyzed, and a modified RAM was developed.Results: Among 47 patients, 5 (10.6%) developed VTE. PROTECHT was the strongest predictor [area under the curve (AUC) = 0.844], followed by Vienna CATS (AUC = 0.781). Adding immature granulocytes and red blood cell count to PROTECHT optimized prediction (AUC = 0.856).Conclusion: Incorporating hematologic parameters into PROTECHT may improve VTE risk prediction in BC patients, warranting further evaluation in larger studies.","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Coagulation & Fibrinolysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MBC.0000000000001367","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The applicability of venous thromboembolism (VTE) risk assessment models (RAMs), to breast cancer (BC) populations remains unclear. We aimed to compare the efficacy of current RAMs and examine the potential of additional hematologic parameters and thromboelastography (TEG); a point of care test, in improving VTE prediction in breast cancer (BC) patients.

Methods: In this pilot study, female BC patients were recruited before chemotherapy and followed for 6-12 months for VTE. VTE risk was assessed using Khorana score, Vienna CATS, PROTECHT, COMPASS-CAT, New Vienna CATSCORE, MDACC CAT, and hypercoagulability status. TEG and hematologic parameters were analyzed, and a modified RAM was developed.

Results: Among 47 patients, 5 (10.6%) developed VTE. PROTECHT was the strongest predictor [area under the curve (AUC) = 0.844], followed by Vienna CATS (AUC = 0.781). Adding immature granulocytes and red blood cell count to PROTECHT optimized prediction (AUC = 0.856).

Conclusion: Incorporating hematologic parameters into PROTECHT may improve VTE risk prediction in BC patients, warranting further evaluation in larger studies.

查看原文本刊更多论文

利用化疗前血液学和凝血学特征加强对乳腺癌血栓形成的预测。

静脉血栓栓塞（VTE）风险评估模型（RAMs）对乳腺癌（BC）人群的适用性尚不清楚。我们的目的是比较当前RAMs的疗效，并检查其他血液学参数和血栓弹性成像（TEG）的潜力；一种护理点测试，用于改善乳腺癌（BC）患者的静脉血栓栓塞预测。方法：在这项初步研究中，在化疗前招募女性BC患者，随访6-12个月进行静脉血栓栓塞治疗。使用Khorana评分、Vienna CATS、protect、COMPASS-CAT、New Vienna CATSCORE、MDACC CAT和高凝状态评估静脉血栓栓塞风险。分析了TEG和血液学参数，开发了改进的RAM。结果：47例患者中，5例（10.6%）发生静脉血栓栓塞。protect是最强的预测因子[曲线下面积(AUC) = 0.844]，其次是Vienna CATS （AUC = 0.781）。将未成熟粒细胞和红细胞计数加入PROTECHT优化预测（AUC = 0.856）。结论：将血液学参数纳入PROTECHT可改善BC患者静脉血栓栓塞风险预测，值得在更大规模的研究中进一步评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Coagulation & Fibrinolysis 医学-血液学

CiteScore

1.90

自引率

0.00%

发文量

111

审稿时长

4-8 weeks

期刊介绍： Blood Coagulation & Fibrinolysis is an international fully refereed journal that features review and original research articles on all clinical, laboratory and experimental aspects of haemostasis and thrombosis. The journal is devoted to publishing significant developments worldwide in the field of blood coagulation, fibrinolysis, thrombosis, platelets and the kininogen-kinin system, as well as dealing with those aspects of blood rheology relevant to haemostasis and the effects of drugs on haemostatic components